Good morning :)
$
₹
Revolution Medicines Inc

Revolution Medicines Inc

RVMD

NASDAQ
Asset Logo

Revolution Medicines Inc

RVMD

NASDAQ
$209.381.11% (-2.35)
$
₹
$209.381.11% (-2.35)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $46.0B the stock is ranked 355

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

17.77
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-8.8
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 12 analysts' reports

Buy
12 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +5.94% price upside over the next year

Current Price$209.38
Target Price$221.90

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
73.06
73.06
1Y Return
25.87%
25.87%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
26.37
26.37
1Y Return
50.81%
50.81%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
26.68%
26.68%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.77
30.77
1Y Return
37.88%
37.88%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.03
20.03
1Y Return
39.6%
39.6%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Revolution Medicines Inc -17.77-
AbbVie Inc73.0650.450.42
Amgen Inc26.3719.682.23

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-305.2
-364.8
-453.8
-644.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue000261.59000000
Net Income-116-133.23-156.28-194.56-213.41-247.78-305.20-364.89-453.81-644.37
Net Profit Margin----74.37%------
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. What is Revolution Medicines Inc's share price today?

    Revolution Medicines Inc (RVMD) share price today is $209.38 as of August 22, 2026 at 1:30 AM IST. The stock touched a day high of $212.69 and a day low of $206.73.

  2. What exchange does Revolution Medicines Inc stock trade on, and under what ticker symbol?

    Revolution Medicines Inc stock trades on NASDAQ under the ticker symbol RVMD.

  3. What is Revolution Medicines Inc's market capitalization?

    Revolution Medicines Inc's market capitalization is $46B as of August 22, 2026 at 1:30 AM IST.

  4. What is Revolution Medicines Inc's price-to-earnings (P/E) ratio?

    Revolution Medicines Inc's price-to-earnings (P/E) ratio is N/A as of August 21, 2026.

  5. What is Revolution Medicines Inc's price-to-book (P/B) ratio?

    Revolution Medicines Inc's price-to-book (P/B) ratio is 17.77 as of August 21, 2026.

  6. Can Indian investors buy Revolution Medicines Inc shares?

    Yes, You can buy Revolution Medicines Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. How can I invest in Revolution Medicines Inc shares from India?

    Indian investors can buy Revolution Medicines Inc shares in three steps: 1. Search Revolution Medicines Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. How does USD-INR currency movement affect returns from Revolution Medicines Inc shares for Indian investors?

    Since Revolution Medicines Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. What is the minimum amount required to invest in Revolution Medicines Inc shares via Tickertape?

    Indian investors can start investing in Revolution Medicines Inc (RVMD) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0477 shares at the current price of $209.38.

Loading...